Evolution of myeloproliferative neoplasms from normal blood stem cells
Open Access
- 5 December 2024
- journal article
- Published by Ferrata Storti Foundation (Haematologica) in Haematologica
- Vol. 110 (4) , 840-849
Abstract
Over the course of the last decade, genomic studies in the context of normal human hematopoiesis have provided new insights into the early pathogenesis of myeloproliferative neoplasms (MPN). A preclinical phase of MPN, termed clonal hematopoiesis was identified and subsequent lineage tracing studies revealed a multi-decade long time interval from acquisition of an MPN phenotypic driver mutation in a hematopoietic stem cell to the development of overt MPN. Multiple germline variants associated with MPN risk have been identified through genome-wide association studies and in some cases functional interrogation of the impact of the variant has uncovered new insights into hematopoietic stem cell biology and MPN development. Increasingly sophisticated methods to study clonal contributions to human hematopoiesis and measure hematopoietic stem cell fitness have helped to discern the biology underlying the tremendous clinical heterogeneity observed in MPN. Despite these advances, significant knowledge gaps remain, particularly with respect to germline genetic contributors to both MPN pathogenesis and phenotypic diversity, as well as limitations in the ability to prospectively quantify rates of clonal expansion in individual MPN patients. Ultimately, we envisage a personalized approach to MPN care in the future, in which an individualized genetic assessment can predict MPN trajectory and this information will be used to inform and guide therapy. MPN is particularly amenable to precision medicine strategies and our increased understanding of the evolution of MPN from normal blood stem cells provides a unique opportunity for early therapeutic intervention approaches and potentially MPN prevention strategies.Keywords
This publication has 75 references indexed in Scilit:
- The JAK2 46/1 haplotype predisposes to MPL-mutated myeloproliferative neoplasmsBlood, 2010
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor CellsCancer Cell, 2010
- Pegylated Interferon Alfa-2a Yields High Rates of Hematologic and Molecular Response in Patients With Advanced Essential Thrombocythemia and Polycythemia VeraJournal of Clinical Oncology, 2009
- A common JAK2 haplotype confers susceptibility to myeloproliferative neoplasmsNature Genetics, 2009
- JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasmsNature Genetics, 2009
- A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasmsNature Genetics, 2009
- Hematopoiesis: An Evolving Paradigm for Stem Cell BiologyCell, 2008
- A single type of progenitor cell maintains normal epidermisNature, 2007
- The journey of developing hematopoietic stem cellsDevelopment, 2006
- Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the diseaseBlood, 2003